Advanced Lung Cancer
Conditions
Interventions
A:docetaxel and platinum
B:chemotherapy plus rmhTNF
Sponsors
Clinical Pharmacology Research Base of West China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Eligible patients (older than 18 years) were required to have histologically or cytologically con?rmed stage IIIB/IV NSCLC. Other inclusion criteria were measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors (RECIST version 3.0), an European Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, predicted life expectancy longer than at least 12weeks from ?rst study-drug dose, and adequate hematologic, hepatic, cardiac and renal function. A washout period from previous treatments was required (2 to 6 weeks).
Exclusion criteria
Exclusion criteria: Exclusion criteria included hemoptysis (1/2 tsp or more per event); central nervous system metastases; pregnancy or lactation; a history of documented hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of aspirin (more than 325 mg per day), nonsteroidal antiinflammatory agents, or other agents known to inhibit platelet function; a history of hypersensitivity to paclitaxel, polypeptide drugs or biologics; and previous exposure to taxanes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| responds survival; | — |
Countries
China
Contacts
Public ContactYingqi Zhang
Outcome results
None listed